This company is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants.
1 Like
Results of £6.22m bookbuild raise today at 9p per share
Verici Dx PLC - Result of Placing #VRCI @VericiDx Verici Dx PLC - Result of Placing - Vox Markets #voxmarkets
Verici Dx PLC - Publication of Circular #VRCI @VericiDx Verici Dx PLC - Publication of Circular - Vox Markets #voxmarkets
This one is probably off radar for most but…
VRCI Verici Dx
3 products ready for commercialisation.
First deal with Thermofisher ($218bn market cap) announced late 23. More to follow.
Recent bookbuild added to their existing cash & revenue funds them well into 2026.
Near 2 thirds of bookbuild taken by 3 institutions (see last tr1 RNS’s). Bookbuild filled in 3 hours. Retail offer everyone applications scaled back by around half.
Products are Tutivia, Clarava, Protega.
Products - blood assays to accurately determine risk of transplant rejection. New products being developed.
“The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.”
Info:
1 Like
Another institution getting involved. Feels like plenty wanted in this and wonder why…
1 Like
Renx possibly being taken out. Eyes will be monitoring here too imo… considering we are a spin out from RENX
1 Like
Still holding this, in bargain territory now, 15% under 9p fund raise that gave them a cash runway until 2026.
Licence deal with Thermofisher and recurring revenue… more to come as it was non exclusive
Majority of fund raise taken by institutional investment (read tr1 RNS after fund raising) … only dropped due to shocking market and end of year tax selling in March imo.
This is one small pharma that deserves attention
1 Like